Metastatic Non Small Cell Lung Cancer Nsclc clinical trials

Explore recruiting metastatic non small cell lung cancer nsclc clinical trials.

Recruiting metastatic non small cell lung cancer nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Non Small Cell Lung Cancer Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Open-label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer

Spain, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Poland, Netherlands, Hungary, Bulgaria, Estonia, Ireland +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer

Czechia, Poland, Greece, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Belgium, France, Spain, Germany, Austria, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metastatic Non Small Cell Lung Cancer Nsclc trials by city

Metastatic Non Small Cell Lung Cancer Nsclc in Toronto Metastatic Non Small Cell Lung Cancer Nsclc in Vancouver Metastatic Non Small Cell Lung Cancer Nsclc in Montreal Metastatic Non Small Cell Lung Cancer Nsclc in Calgary Metastatic Non Small Cell Lung Cancer Nsclc in Edmonton Metastatic Non Small Cell Lung Cancer Nsclc in Ottawa Metastatic Non Small Cell Lung Cancer Nsclc in Winnipeg Metastatic Non Small Cell Lung Cancer Nsclc in Quebec City Metastatic Non Small Cell Lung Cancer Nsclc in Hamilton Metastatic Non Small Cell Lung Cancer Nsclc in Kitchener Metastatic Non Small Cell Lung Cancer Nsclc in London Metastatic Non Small Cell Lung Cancer Nsclc in Halifax Metastatic Non Small Cell Lung Cancer Nsclc in New York Metastatic Non Small Cell Lung Cancer Nsclc in Los Angeles Metastatic Non Small Cell Lung Cancer Nsclc in Chicago Metastatic Non Small Cell Lung Cancer Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease